Oncotelic Therapeutics and Sapu Bioscience Define Sub-15 nm Nanoparticles as New Frontier in Drug Delivery

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and joint venture partner Sapu Bioscience have announced the publication of their comprehensive review article in the International Journal of Molecular Sciences. The paper, titled "Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential," represents the first systematic examination of nanoparticles exclusively within the 5–15 nm range, establishing this emerging scale as poised to redefine nanomedicine. Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, the research highlights how these sub-15 nm systems achieve deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across biological barriers including the blood-brain barrier.

The publication, available at https://doi.org/10.3390/ijms262210842, establishes a new pharmacological paradigm that could overcome the delivery and toxicity limitations of both small molecules and larger nanocarriers. This breakthrough size regime represents a significant advancement in drug delivery technology, potentially enabling more effective treatments for challenging medical conditions where current delivery systems fall short. The research demonstrates that nanoparticles in this specific size range exhibit unique properties that distinguish them from both smaller molecular drugs and larger nanoparticle systems currently in use.

The implications of this research extend across multiple therapeutic areas, particularly in oncology and diseases requiring crossing of biological barriers. The enhanced ability of sub-15 nm nanoparticles to penetrate tissues more deeply and clear from the body more rapidly addresses key limitations of existing nanomedicine approaches. This could lead to improved therapeutic outcomes with reduced side effects, as the smaller particles are less likely to accumulate in organs and cause long-term toxicity concerns that have plagued some larger nanoparticle systems.

The joint research effort between Oncotelic Therapeutics and Sapu Bioscience represents a significant contribution to the field of nanomedicine, providing a comprehensive framework for future development of drug delivery systems. The establishment of sub-15 nm nanoparticles as a distinct and advantageous size category opens new possibilities for therapeutic development, particularly for conditions where targeted delivery and barrier penetration have been major challenges. This research provides the scientific foundation for next-generation nanomedicine approaches that could transform treatment paradigms across multiple disease areas.